Pembrolizumab-Induced Thyroiditis and Colitis—Presentation and Resolution on Serial FDG PET/CT
Searle, Julie Lyburn, Iain
Searle, Julie
Lyburn, Iain
Glos Author
Date
2021-02
Journal Title
Subject
Type
Journal Article
Collections
Abstract
A 58-year-old man with previous melanoma of the left leg underwent whole-body 18F-FDG PET/CT to stage metastatic disease prior to commencing pembrolizumab. Follow-up FDG PET/CT after 3 months of treatment showed partial metabolic response of soft tissue and nodal metastases and diffuse increased thyroid and colonic uptake, suggestive of thyroiditis and colitis. Pembrolizumab was ceased, and a repeat FDG PET/CT scan showed regression of uptake in the thyroid gland and colon, in keeping with resolution of inflammatory change. Immune-related adverse events induced by Immune checkpoint inhibitors, such as pembrolizumab, should be recognized-cessation of treatment often leads to resolution.
Citation
Nawwar, A. A., Searle, J., & Lyburn, I. D. (2021). Pembrolizumab-Induced Thyroiditis and Colitis-Presentation and Resolution on Serial FDG PET/CT. Clinical nuclear medicine, 46(2), e121–e122. https://doi.org/10.1097/RLU.0000000000003306